STELARA™ is a human IgG1k monoclonal antibody against the p40 subunit of the IL-12 and IL-23 cytokines. Using DNA recombinant technology, STELARA™ is produced in a well characterized recombinant cell line and is purified using standard bio-processing technology. The manufacturing process contains steps for the clearance of viruses. STELARA™ is comprised of 1326 amino acids and has an estimated molecular mass that ranges from 148,079 to 149,690 Daltons. STELARA™ is available as: 45 mg of ustekinumab in 0.5 mL and 90 mg of ustekinumab in 1 mL.
STELARA™ is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Media Articles Related to Stelara (Ustekinumab)
Brodalumab Beats Stelara in Psoriasis Trial, Sponsors Say
Source: MedPage Today Dermatology [2014.11.11]
(MedPage Today) -- More patients achieve total plaque clearance in topline results.
Several Treatment Options May Improve Nail Psoriasis
Source: Medscape Dermatology Headlines [2014.12.10]
Treatment of nail psoriasis poses a clinical challenge and may ultimately require more than one approach, according to new best practice recommendations.
Reuters Health Information
Picture of Psoriasis 1
Source: MedicineNet Psoriasis Specialty [2014.12.09]
Title: Picture of Psoriasis 1
Created: 11/11/2009 4:29:00 PM
Last Editorial Review: 12/9/2014 12:00:00 AM
Positive results from third and final pivotal Phase 3 study of brodalumab in patients with moderate-to-severe plaque psoriasis announced
Source: Dermatology News From Medical News Today [2014.11.28]
Amgen and AstraZeneca have announced that AMAGINE-2(TM), a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis...
Positive results from second pivotal Phase 3 study of Brodalumab in patients with moderate-to-severe plaque psoriasis announced
Source: Dermatology News From Medical News Today [2014.11.13]
Amgen and AstraZeneca has announced that AMAGINE-3(TM), a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis...
Published Studies Related to Stelara (Ustekinumab)
Efficacy and safety of ustekinumab in Chinese patients with moderate to severe
plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). 
moderate to severe plaque-type psoriasis... CONCLUSIONS: Consistent with results previously reported in global phase 3
An update on the long-term safety experience of ustekinumab: results from the
psoriasis clinical development program with up to four years of follow-up. 
severe psoriasis treated for up to four years... CONCLUSION: The safety profile of long-term ustekinumab treatment with up to four
Long-term safety experience of ustekinumab in patients with moderate to severe
psoriasis (Part II of II): results from analyses of infections and malignancy
from pooled phase II and III clinical trials. 
exposed up to 3 years... CONCLUSIONS: The emerging safety profile of ustekinumab remains favorable and
Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe
plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. 
This phase 2/3, double-blind, placebo-controlled study was designed to assess the
safety and efficacy of ustekinumab in Japanese patients with moderate-to-severe
plaque-type psoriasis. Overall, 158 patients were randomized to receive
ustekinumab 45 or 90 mg at weeks 0, 4, and every 12 weeks, or placebo with
cross-over to ustekinumab at week 12...
Long-term safety experience of ustekinumab in patients with moderate-to-severe
psoriasis (Part I of II): results from analyses of general safety parameters from
pooled Phase 2 and 3 clinical trials. 
ustekinumab through 3 years of treatment... CONCLUSIONS: The safety profile of continued ustekinumab exposure through up to 3
Clinical Trials Related to Stelara (Ustekinumab)
A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis [Recruiting]
The purpose of this study is to evaluate the efficacy (good or bad effects) and safety of
ustekinumab in the treatment of patients with moderate to severe psoriasis in China.
Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis [Recruiting]
This study will provide data on sasety and efficacy of Ustekinumab in patients suffering
from Palmo-Plantar Pustular Psoriasis (PPPP) or Palmo-Plantar Pustulosis(PPP)
A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS) [Recruiting]
This is a study of the safety and efficacy of ustekinumab (CNTO 1275) in adolescent patients
with moderate to severe psoriasis.
TRANSIT - A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate [Recruiting]
This purpose of this study is to assess the safety of ustekinumab in psoriasis patients who
receive ustekinumab following an inadequate response to methotrexate therapy. The study
will provide information for doctors on how to manage the transfer from methotrexate to the
biologic agent ustekinumab. The study is designed to compare two methods of transferring
patients from methotrexate to ustekinumab. The two methods being compared are
discontinuation of methotrexate with immediate initiation of ustekinumab versus initiation
of ustekinumab with overlap and gradual dose reduction of methotrexate over 4 weeks.
A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid [Recruiting]
The purpose of this study is to evaluate the efficacy and safety of ustekinumab in patients
with primary biliary cirrhosis who had an inadequate response to ursodeoxycholic acid.
Reports of Suspected Stelara (Ustekinumab) Side Effects
Myocardial Infarction (71),
Drug Ineffective (67),
OFF Label USE (41),
Drug Dose Omission (34),
Psoriatic Arthropathy (34), more >>